Oliver O'Connor

Oliver O'Connor, Chief Executive of the Irish Pharmaceutical Healthcare Association, discusses a new four-year deal aimed at expediting access to innovative medicines for public patients in Ireland. He highlights a redesign of legal timelines to ensure decisions are made within 180 days. O'Connor also shares insights on which treatments, including those for cancer and rare diseases, will be prioritized. Additionally, he touches on trade concerns related to US-EU relations and the ongoing negotiations around the anti-obesity drug Manjaro.